Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct.
The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.
Along with the boxed warning, FDA will require a statement on product labeling indicating that TXA injection is contraindicated as a neuraxial injection, and have the dose and administration section ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback